

Docket No.: 240950US0DIV

OBLON
SPIVAK
MCCLELLAND
MAIER
A
NEUSTADT

P.C.
ATTORNEYS AT LAW

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/646,825

Applicants: Yoshinao NAGASHIMA, et al.

Filing Date: August 25, 2003

For: AUTONOMIC NERVE REGULATING AGENT

Group Art Unit: 1614

Group Art Unit: 1614 "RESPONSE UNDER 37 CFR 1.116Examiner: GEMBEH, Shirley V. EXPEDITED PROCEDURE EXAMINING

GROUP 1614 "

SIR: Attached hereto for filing are the following papers:

RESPONSE AND REQUEST FOR RECONSIDERATION Under 37 C.F.R. 1.116

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Richard L. Chinn, Ph.D. Registration No. 34,305

Customer Number

22850

(703) 413-3000 (phone) (703) 413-2220 (fax) DOCKET NO: 240950US0DIV

& TRADEMARK OFFICE IN THE UNITED STATE

IN RE APPLICATION OF

: EXAMINER: GEMBEH, SHIRLEY V.

YOSHINAO NAGASHIMA. ET AL.

SERIAL NO: 10/646,825

FILED: AUGUST 25, 2003

: GROUP ART UNIT: 1614

FOR: AUTONOMIC NERVE REGULATING AGENT

"RESPONSE UNDER 37 CFR 1.116-EXPEDITED PROCEDURE EXAMINING

RESPONSE AND REQUEST FOR RECONSIDERATION

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Responsive to the Official Action of March 27, 2007, reconsideration of the aboveidentified application is respectfully requested in view of the following remarks.

REQUEST FOR RECONSIDERATION

Claims 20-24 remain active in this application.

The claimed invention is directed to a vaporization system comprising a vaporization promoting element and specific sesquiterpene alcohol comprising compositions wherein the composition has no odor above a detectable threshold. Applicants have discovered that, in the absence of impurities which can provide a detectable odor, the claimed sesquiterpene alcohols provide efficacy as autonomic nerve regulating agents, suitable for vaporization.

Applicants wish to thank examiner Gembeh for withdrawing all prior rejections in favor of the single rejection under 35 U.S.C. 112, first paragraph, for written description/new matter